Pfizer PT receives Investment Bank Analyst Rating Update
- ByInvesting.com-
Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| NYSE | USD | Real-time | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Frankfurt | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Hamburg | EUR | Delayed | ||
| Xetra | EUR | Delayed | ||
| Santiago | USD | Delayed | ||
| Buenos Aires | ARS | Delayed | ||
| BM&FBovespa | BRL | Delayed | ||
| Vienna | EUR | Delayed | ||
| KASE | USD | Delayed | ||
| Colombia | COP | Delayed | ||
| Lima | USD | Delayed |
By Davit Kirakosyan Citi lowered the price target on McDonald’s (NYSE:MCD) to $277.00 from $279.00 while maintaining a Neutral rating. McDonald's reported its Q4 results...
By Sam Boughedda After a dip earlier in the session, AbbVie (NYSE:ABBV) shares are now slightly up on the day, holding steady, despite Amgen (NASDAQ:AMGN) announcing AMJEVITA, a...
2022. Earnings per share came in at $1.14, versus the expected $1.05.The reported revenue of $24.29 billion represents growth of 7.30% compared to the previous quarter, and growth...
Pfizer Stumbles As Vaccine Demand Expected To Slide Pfizer Inc shares slid as much as 3.5% in premarket trading (before bouncing back) after the company forecasted COVID-19 vaccine...
Pfizer came out with quarterly earnings of $1.14 per share.
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operations through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation & Immunology. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. Its Vaccines include Comirnaty/BNT162b2, the Prevnar family, Nimenrix and others. Its Oncology products include Ibrance, Xtandi, Inlyta, Sutent, Retacrit, Lorbrena and Braftovi. Its Internal Medicine products include Eliquis and the Premarin family. Its Inflammation & Immunology products include Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis and Cibinqo. It also offers Rimegepant and Zavegepant.
| Average | 54.30 (+22.96% Upside) |
| High | 75.00 |
| Low | 44.00 |
| Price | 44.16 |
| No. of Analysts | 20 |
Type | Daily | Weekly | Monthly |
|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 60.10 | 60.86 | 57.24 | +2.02 | +3.48% | 4.20M | London | |||
| 1.19 | 1.19 | 1.19 | 0.00 | 0.00% | 0.00 | London | |||
| 230.00 | 230.00 | 230.00 | +2.50 | +1.10% | 17.89K | London | |||
| 1.89 | 1.89 | 1.89 | 0.00 | 0.00% | 0.00 | London | |||
| 12.75 | 12.75 | 12.75 | 0.00 | 0.00% | 0.00 | London | |||
| 177.90 | 178.50 | 178.50 | -0.600 | -0.34% | 1.46K | London | |||
| 237.50 | 235.00 | 227.00 | +2.00 | +0.86% | 713.37K | London | |||
| 10,484.80 | 10,626.00 | 10,472.00 | -104.0 | -0.98% | 374.83K | London | |||
| 1,411.80 | 1,445.00 | 1,405.00 | -11.60 | -0.81% | 1.70M | London | |||
| 83.20 | 87.50 | 83.10 | -3.50 | -4.04% | 133.88K | London | |||
| 3.98 | 3.98 | 3.98 | +0.5000 | +14.49% | 3.69M | London | |||
| 45.27 | 45.50 | 43.70 | +1.13 | +2.56% | 1.69M | London | |||
| 186.40 | 187.03 | 184.68 | +0.56 | +0.30% | 5.51M | London | |||
| 0.44 | 0.43 | 0.43 | +0.05 | +12.74% | 558.19M | London | |||
| 2.177 | 2.177 | 2.177 | +0.150 | +7.50% | 1.39M | London |